Molecular Insight has presented clinical data on prostate cancer diagnostic at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto. The clinical data was presented on Trofex, a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer.
Trofex targets prostate specific membrane antigen (PSMA) and has the potential to both detect and to treat metastatic prostate cancer.
The study was initiated in 2008 in patients with prostate cancer and confirmed hormone refractory metastatic disease. The study evaluated Trofex compounds, MIP-1072 and MIP-1095, for their capacity to visualize the disease and to define their pharmacokinetic profiles.
John Babich, Executive Vice President, CSO and President of Research and Development at Molecular Insight, said: Based on the potential demonstrated here, to rapidly and clearly image prostate cancer, we have planned additional studies to investigate the performance of these radiolabeled small molecules in patients with metastatic prostate cancer.”